Orphazyme reports business highlights and financial results in Interim Report First Half 2021
Retrieved on:
星期二, 八月 31, 2021
Journal of Inherited Metabolic Disease, Emergency Use Authorization, Journal, ALS, EMA, CHMP, Interim, Marginal cost, Market Access Program, ATU, DKK, JIMD, FTE, Research, Endpoint security, Management, Inclusion body myositis, Review, Safety, EAP, HIV disease progression rates, Patient, IBM, Conference, Sale, FDA, Q&A, Animal, Pharmaceutical industry
Copenhagen,Denmark,August 31,2021 Orphazyme A/S (ORPHA.CO; ORPH) (the Company), a late-stage biopharmaceutical company, today announces its Interim Report First Half 2021 for the period January 1 June 30, 2021.
Key Points:
- Copenhagen,Denmark,August 31,2021 Orphazyme A/S (ORPHA.CO; ORPH) (the Company), a late-stage biopharmaceutical company, today announces its Interim Report First Half 2021 for the period January 1 June 30, 2021.
- We anticipate reaching net revenues of between DKK 30 and DKK 40 million by year-end December 31, 2021.
- Orphazyme will host an investor call during which Management will present the Interim Report First Half 2021.
- The call will be held on Tuesday, August 31, 2021 at 2.00 PM CEST/8.00 AM EDT.